Dr Rachel Giles guides us through 7 abstracts from the MTIS Virtual Symposium 2020:
- OVERCOME study: Improvement of migraine using CGRP mAbs in a real-world setting. Shapiro et al.
- Remote electrical neuromodulation useful for adolescents with migraine. Hershey et al.
- GLADIATOR trial: No new cardiovascular safety concerns with long-term use of lasmiditan. Hochstetler
- CONQUER trial: Less medication use and doctor visits with galcanezumab in treatment-resistant migraine. Gomez et al.
- TELESCOPE trial: Real-world evidence reveals physiciansâ perception of erenumab. Koch et al.
- FOCUS and HALO studies: Fremanezumab effective in patients with migraine and comorbid depression
- PREDICT trial: Long-term onabotulinumtoxinA improves quality of life in migraine
Posted on
Previous Article
« Per-oral endoscopic myotomy “reasonable” first-line treatment for idiopathic achalasia Next Article
Polygenic risk score could spot people at higher risk for abdominal aortic aneurysm »
« Per-oral endoscopic myotomy “reasonable” first-line treatment for idiopathic achalasia Next Article
Polygenic risk score could spot people at higher risk for abdominal aortic aneurysm »
Table of Contents: MTIS 2020
Featured articles
Contents
Improvement of migraine using CGRP mAbs in a real-world setting
Similar treatment needs for high-frequency episodic and low-frequency chronic migraine
Nitroglycerin-induced cluster headache attacks characterised comprehensively
Remote electrical neuromodulation useful for adolescents with migraine
Concomitant preventive medication has no impact on efficacy of ubrogepant
No new cardiovascular safety concerns with long-term use of lasmiditan
Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine
Real-world evidence reveals physiciansâ perception of erenumab
Early initiation of lasmiditan improves migraine outcomes
Fremanezumab effective in patients with migraine and comorbid depression
Long-term onabotulinumtoxinA improves quality of life in migraine
Sustained shift in migraine status using galcanezumab
Long-term efficacy and safety of fremanezumab in treatment-resistant migraine
Related Articles
November 8, 2021
Telemedicine beneficial for headache care during the pandemic
March 12, 2021
Many nonpharmacological options to treat pediatric migraine
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com